Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Fase 2, open-label studie om de veiligheid en verdraagbaarheid van progerinine bij het syndroom van Werner te evalueren

30 september 2026 bijgewerkt door: PRG Science & Technology Co., Ltd.

Een open-label fase 2-onderzoek om de veiligheid en verdraagbaarheid van progerinine te evalueren voor de behandeling van botmineraaldichtheidsverlies (BMD) bij proefpersonen met het typische syndroom van Werner

This is a Phase 2, open-label study to A Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin for the Treatment of Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.

There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Subjects who have successfully completed the Screening phase will enter the baseline and treatment phase of the study. Subjects will take the assigned treatment of Progerinin (2400 mg) split as 1200 mg BID in the morning and evening with food for 1-Year.

To evaluate the safety and tolerability of Progerinin for the treatment of BMD loss in subjects with typical Werner syndrome.

The secondary objectives of this study are:

  • To characterize the activity of Progerinin on bone metabolism in subjects with typical Werner Syndrome.
  • To evaluate vascular function in subjects with typical Werner Syndrome.
  • To evaluate glucose metabolism and insulin resistance in subjects with typical Werner Syndrome.
  • To evaluate lipid metabolism in subjects with typical Werner Syndrome.
  • To evaluate physical function in subjects with typical Werner Syndrome.
  • To evaluate the pharmacokinetics (PK) of Progerinin sachet administered twice daily (BID) in subjects with typical Werner Syndrome.

Studietype

Ingrijpend

Inschrijving (Geschat)

5

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48109
        • Werving
        • University of Michigan

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

[Inclusion Criteria]

  1. Subjects must be at least ≥ 18 years of age.

  2. Subjects should have a confirmed diagnosis of typical Werner syndrome by genetic analysis.

  3. Subjects should be osteopenic (T-score between -1.0 and -2.5) or have confirmed osteoporosis (T-score ≤ -2.5) at screening/baseline. Subjects may continue to receive bone supplements (e.g., bisphosphonates, calcium supplements, Vitamin D supplements, etc.) as appropriate per standard of care throughout the study.

  4. Male or non-pregnant, non-lactating female.

  5. Subjects screening blood chemistry inclusive of metabolic panel, hematology, and urine analysis results should be acceptable to the investigator.

  6. Negative pregnancy test for female subjects as described below. Women of child bearing potential (WOCBP) and Women not of child-bearing potential are eligible to participate. Both women of childbearing potential and women of non-child-bearing potential should use an approved method of birth control and agrees to continue to use this method for the duration of the study and for 90 days after last treatment.

    Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile or two years post-menopausal. All male subjects/partners must agree to use a In addition, subjects may not donate sperm for the duration of the study and for 90 days after last treatment.

    Females who are less than two (2) years post-menopausal, those with tubal ligations and those using contraception must have a negative serum pregnancy test at baseline within the one (1) week prior to the first study medication administration. Every six weeks, and at study termination a pregnancy test should be performed, either serum or urine stick test. However, if the urine result is positive, a serum pregnancy test will be performed.

  7. Provide signed written informed consent and willingness, ability to comply with study requirements.

  8. Subject must have a projected life expectancy of ≥ 12 months in the opinion of the Investigator.

[Exclusion Criteria]

  1. Subject with clinical signs seen at screening are at the final stage of Werner syndrome progression, and completion of the study is difficult to be assessed, including:

    • Subjects who received continuous or intermittent home oxygen therapy for 6 months before obtaining consent
    • Subjects who received at least 2 hospitalizations for pneumonia during the 12 months prior to obtaining consent
    • Subjects who have at least 10% net weight loss and have not recovered. This includes significant net weight loss over the last six months.
  2. Subjects with significant dehydration as judged by the principal investigator.

  3. Subjects with pericardial fluid, ascites and pleural effusion.

  4. Therapy with investigational drugs within 30 days of beginning study medication.

  5. History of prior malignancy, except for adequately treated in situ cancer, basal cell, squamous cell skin cancer, or other cancers (e.g., breast, prostate) for which the subject has been disease-free for at least 3 years.

  6. Any serious medical condition, laboratory abnormality, psychiatric illness, or comorbidity that, in the judgment of the Investigator, would make the subject inappropriate for the study.

  7. Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires intravenous (IV) treatment for infection(s).

  8. Subjects with known history of having Acquired Immunodeficiency Syndrome (AIDS) or with a history known to be infected with Human Immunodeficiency Virus (HIV).

  9. Subjects with a history of serious drug hypersensitivity or allergic reaction such as anaphylaxis or any component of the formulation.

  10. Clinically significant bleeding within 2 weeks prior to baseline (e.g., gastrointestinal [GI] bleeding, intracranial hemorrhage).

  11. Medical or recreational use of marijuana or THC-containing compounds within 3 months of screening visit and for the duration of the trial.

  12. Pregnant or lactating women.

  13. Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e., larger than what is required for placement of central venous access, percutaneous feeding tube, or biopsy), within 28 days prior to baseline or anticipated surgery during the study period.

  14. Inability to return for scheduled treatment and assessments.

  15. Subjects that require concomitant use of any medications or substances that are strong inhibitors or inducers of CYP2D6 or CYP2C8

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Treatment Group

all subjects will receive Progerinin 2400mg (1200mg twice daily) after morning and evening meals for a year

This is a Phase 2, open-label study to evaluate the safety and Tolerability of Progerinin for the treatment of BMD Bone Mineral Density (BMD) Loss in Subjects with Typical Werner Syndrome.

. There will be up to 5 subjects that will receive treatment with Progerinin twice daily for approximately 1 year. This study will have three phases: Screening Phase, Treatment Phase, and Follow-Up Phase.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)

The intensity of the event will be graded using CTCAE v6.0 criteria

Baseline to Week 56 (including 4-week follow-up)
Incidence of Treatment-Related Adverse Events
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Incidence of Serious Adverse Events (SAEs)
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Incidence of TEAEs and SAEs leading to discontinuation of study medication
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Blood Chemistry from Baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Hematology from Baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Urinalysis Results from Baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Height (cm) from Baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Weight (kg) from baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Temperature (°C) from baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Pulse Rate (beats per minute) from baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Respiratory Rate (breaths per minute) from baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Systolic Blood pressure (mmHg) from baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Diastolic Blood pressure (mmHg) from baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Changes in Physical Examination findings from baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG Ventricular Rate (beats per minute) from baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG PR interval (msec) from baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG QRS interval (msec) from baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG QT interval (msec) from baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)
Change in ECG QTc interval (msec) from baseline
Tijdsspanne: Baseline to Week 56 (including 4-week follow-up)
Baseline to Week 56 (including 4-week follow-up)

Secundaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
Change in Femur Bone Mineral Density (BMD) from baseline
Tijdsspanne: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Lumbar Spine BMD from baseline
Tijdsspanne: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Aortic Pulse Wave Velocity (m/s) from baseline
Tijdsspanne: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Insulin Resistance by Oral Glucose Tolerance Test (OGTT) from baseline
Tijdsspanne: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Lipid Profile from baseline
Tijdsspanne: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Handgrip Strength Test from baseline
Tijdsspanne: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Short Physical Performance Battery (SPPB) Total Score from baseline
Tijdsspanne: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Ankle-Brachial Pressure Index (ABPI) from baseline
Tijdsspanne: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Bone-Specific Alkaline Phosphatase (BAP) from baseline
Tijdsspanne: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Osteocalcin (OC) from baseline
Tijdsspanne: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Procollagen Peptides (P1NP) from baseline
Tijdsspanne: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in Deoxypyridinium (DPD) from baseline
Tijdsspanne: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Change in C-Terminal Telopeptide of Type 1 Collagen (CTX) from baseline
Tijdsspanne: Baseline, Week 24, and Week 52
Baseline, Week 24, and Week 52
Pharmacokinetic Parameters of Progerinin at the Specified PK Assessment Visits
Tijdsspanne: Baseline, Week12, Week 24, Week 36 and Week 52
Baseline, Week12, Week 24, Week 36 and Week 52

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 oktober 2026

Primaire voltooiing (Geschat)

1 december 2027

Studie voltooiing (Geschat)

1 december 2027

Studieregistratiedata

Eerst ingediend

31 maart 2023

Eerst ingediend dat voldeed aan de QC-criteria

26 april 2023

Eerst geplaatst (Werkelijk)

6 mei 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

5 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

30 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren